| *Sponsored
(NYSE: SER) Sprints Green Early Tuesday Behind Breaking News (Technicals Remain Triggered)
July 29th Greetings Readers,
Serina Therapeutics, Inc. (NYSE: SER) went green quickly on Tuesday AM.
Could part of that be due to today's breaking news?
Check it out:
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges –
- Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy -
HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the advancement of its novel product candidate, SER-270, a proprietary POZ-conjugated vesicular monoamine transporter 2 (VMAT2) inhibitor in development for the treatment of tardive dyskinesia (TD).
SER-270, also referred to as POZ-VMAT2i, leverages Serina’s proprietary POZ polymer technology to enable long-acting, once weekly subcutaneous administration, offering a potentially transformative alternative to existing oral VMAT2 inhibitors. The candidate is designed to meet the needs of underserved TD patients who struggle with daily medication adherence, including those already managed with long-acting injectable (LAI) antipsychotics.
...
“POZ-VMAT2i embodies Serina’s commitment to solving real-world challenges for patients and caregivers who are often left behind by traditional therapies,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “By targeting non-compliant, institutionalized, and dysphagic patients with a transformative once-weekly injectable, we believe we can meaningfully expand access to proven VMAT2 inhibitor therapy and improve patient lives.”
Read the full article here.
On top of the news, and a run up to approx. $8.00+ in pre-market, SER's float needs to be recognized due to its size (under 3Mn shares).
Due to this small amount of available shares, volatility potential could be significantly heightened.
And as we mentioned previously, SER has multiple technicals triggered over at Barchart.
There's a lot going on here, so I recommend reading my initial report below on (NYSE: SER) and consider this profile for you watchlist. -----
Advancing innovative therapies aimed at addressing challenging neurological conditions, this NYSE American profile is currently flying under-the-radar.
For how long? That's a great question.
With a focus on next-generation molecules, including cann-a-binoids, their work spans diverse central nervous system disorders and beyond.
Collaborations with specialized partners support the exploration of novel RNA-based medicines targeting vaccine immunology, cancer immunotherapy, and gene therapy.
This forward-thinking approach to drug discovery highlights a commitment to unlocking new possibilities in medicine, making the company well worth closer attention for those interested in emerging therapeutic frontiers.
Mix in a low float of fewer than 3Mn shares (meaning volatility potential could be high), a couple of significant analyst targets, a slew of bullish technicals, and recent PR highlights suggesting a company making transformative moves, and there's little doubt why this biopharma idea has hit my radar.
Take a moment to consider pulling up this NYSE American idea:
Serina Therapeutics, Inc. (NYSE: SER)
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications.
Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).
And based on several potential catalysts, (NYSE: SER) has my immediate attention and top watchlist spot. Take a look:
#1. A Low Float Could Create An Environment For Heightened Volatility.
#2. A Pile Of Bullish Technical Indicators May Suggest A Developing Trend Worth Watching Closely.
#3. Serina Provides Business Update Of Recent Company Highlights Signaling Critical Movements Being Made.
#4. Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels.
But more on those in a second...
A Next-Gen Polymer Therapeutic
Serina Therapeutics' proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline).
During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.”
This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates.
As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations.
While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules.
POZ Delivers Key Advantages
POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself. | 
No comments:
Post a Comment